Roberto Pili

  • 10704 Citations
  • 51 h-Index
1990 …2019
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Roberto Pili is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 13 Similar Profiles
Renal Cell Carcinoma Medicine & Life Sciences
Prostatic Neoplasms Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Histone Deacetylase Inhibitors Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Vascular Endothelial Growth Factor A Medicine & Life Sciences
Castration Medicine & Life Sciences
Kidney Neoplasms Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Publications 1990 2019

Antitumor activity and mechanistic characterization of APE1/ReF-1 inhibitors in bladder cancer

Fishel, M. L., Xia, H., McGeown, J., McIlwain, D. W., Elbanna, M., Craft, A. A., Kaimakliotis, H. Z., Sandusky, G. E., Zhang, C., Pili, R., Kelley, M. R. & Jerde, T. J., Jan 1 2019, In : Molecular cancer therapeutics. 18, 11, p. 1947-1960 14 p.

Research output: Contribution to journalArticle

Endonucleases
Urinary Bladder Neoplasms
Oxidation-Reduction
Cisplatin
Cell Proliferation

A Phase Ib Study of Axitinib in Combination with Crizotinib in Patients with Metastatic Renal Cell Cancer or Other Advanced Solid Tumors

Michaelson, M. D., Gupta, S., Agarwal, N., Szmulewitz, R., Powles, T., Pili, R., Bruce, J. Y., Vaishampayan, U., Larkin, J., Rosbrook, B., Wang, E., Murphy, D., Wang, P., Lechuga, M. J., Valota, O. & Shepard, D. R., Jan 1 2019, In : Oncologist.

Research output: Contribution to journalArticle

Open Access
Renal Cell Carcinoma
Maximum Tolerated Dose
Neoplasms
Safety
Vascular Endothelial Growth Factor A

Patient-derived organoids as a potential model to predict response to PD-1/PD-L1 checkpoint inhibitors

Scognamiglio, G., De Chiara, A., Parafioriti, A., Armiraglio, E., Fazioli, F., Gallo, M., Aversa, L., Camerlingo, R., Cacciatore, F., Colella, G., Pili, R. & de Nigris, F., Jan 1 2019, (Accepted/In press) In : British Journal of Cancer.

Research output: Contribution to journalArticle

Open Access
Organoids
Neoplasms
CD8-Positive T-Lymphocytes
Tumor-Infiltrating Lymphocytes
Chordoma

Phase I study of the mTOR inhibitor everolimus in combination with the histone deacetylase inhibitor panobinostat in patients with advanced clear cell renal cell carcinoma

Wood, A., George, S., Adra, N., Chintala, S., Damayanti, N. & Pili, R., Jan 1 2019, (Accepted/In press) In : Investigational New Drugs.

Research output: Contribution to journalArticle

Histone Deacetylase Inhibitors
MicroRNAs
Renal Cell Carcinoma
Maximum Tolerated Dose
Everolimus

Structural variation and fusion detection using targeted sequencing data from circulating cell free DNA

Gawroński, A. R., Lin, Y. Y., McConeghy, B., LeBihan, S., Asghari, H., Koçkan, C., Orabi, B., Adra, N., Pili, R., Collins, C. C., Sahinalp, S. C. & Hach, F., Apr 23 2019, In : Nucleic acids research. 47, 7, p. e38

Research output: Contribution to journalArticle

Open Access
DNA
Neoplasms
Clone Cells
Workflow
Prostatic Neoplasms